Integrins α(v)β3 and α(v)β5 are expressed by endothelium of high- risk neuroblastoma and their inhibition is associated with increased endogenous ceramide

Cancer Research

Volumn 60, Issue 3, 2000, Pages 712-721

  Erdreich Epstein, Anat ^a   Shimada, Hiroyuki ^a   Groshen, Susan ^a   Liu, Ming ^a   Metelitsa, Leonid S ^a   Kim, Kwang Sik ^a   Stins, Monique F ^a   Seeger, Robert C ^a   Durden, Donald L ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; CERAMIDE C2; FIBRONECTIN; INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; VITRONECTIN;

ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CERAMIDES; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRINS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEUROBLASTOMA; RECEPTORS, VITRONECTIN;

EID: 0033960562     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (81)

1. Felding-Habermann, B., and Cheresh, D. A. Vitronectin and its receptors. Curr. Opin. Cell Biol., 5: 864-868, 1993.
2. 6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J. Cell Sci., 111: 2189-2195, 1998.
3. 8 cytoplasmic domain. J. Biol. Chem., 209: 28708-28715, 1994.
4. 1 functions as a receptor for tenascin, fibronectin, and vitronectin. J. Biol. Chem., 270: 23196-23202, 1995.
5. 1 integrins. J. Biol. Chem., 269: 20233-20238, 1994.
6. Aumailley, M., Gurrath, M., Muller, G., Calvete, J., Timpl, R., and Kessler, H. Arg-Gly-Asp constrained within cyclic pentapeptides: strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 291: 50-54, 1991.
7. Cheresh, D. A. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. USA, 84: 6471-6475, 1987.
8. v integrins. Science (Washington DC), 270: 1500-1502, 1995.
9. Klein, S., Giancotti, F. G., Presta, M., Albelda, S. M., Buck, C. A., and Rifkin, D. B. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol. Biol. Cell, 4: 973-982, 1993.
10. v integrin receptors in wound-induced human angiogenesis in human skin/SCID mice chimeras. Am. J. Pathol., 151: 975-983, 1997.
11. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79: 1157-1164, 1994.
12. 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest., 96: 1815-1822, 1995.
13. 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA, 93: 9764-9769, 1996.
14. 3 for angiogenesis. Science (Washington DC), 264: 569-571, 1994.
15. 3 during angiogenesis. J. Clin. Invest., 98: 426-433, 1996.
16. 3 integrin-induced endothelial cell survival. J. Cell Biol., 141: 1083-1093, 1998.
17. Haimovitz-Friedman, A., Cordon-Cardo, C., Bayoumy, S., Garzotto, M., McLoughlin, M., Gallily, R., Edwards, C. K., III, Schuchman, E. H., Fuks, Z., and Kolesnick, R. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J. Exp. Med., 186: 1831-1841, 1997.
18. Robaye, B., Mosselmans, R., Fiers, W., Dumont, J. E., and Galand, P. Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro. Am. J. Pathol., 138: 447-453, 1991.
19. Haimovitz-Friedman, A., Kan, C. C., Ehleiter, D., Persaud, R. S., McLoughlin, M., Fuks, Z., and Kolesnick, R. N. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med., 180: 525-535, 1994.
20. Araki, S., Shimada, Y., Kaji, K., and Hayashi, H. Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation. Biochem. Biophys. Res. Commun., 168: 1194-1200, 1990.
21. Meredith, J. E., Jr., Fazeli, B., and Schwartz, M. A. The extracellular matrix as a cell survival factor. Mol. Biol. Cell, 4: 953-961, 1993.
22. Hannun, Y. A. Functions of ceramide in coordinating cellular responses to stress. Science (Washington DC), 274: 1855-1859, 1996.
23. Verheij, M., Bose, R., Lin, X. H., Yao, B., Jarvis, W. D., Grant, S., Birrer, M. J., Szabo, E., Zon, L. I., Kyriakis, J. M., Haimovitz-Friedman, A., Fuks, Z., and Kolesnick, R. N. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature (Lond.), 380: 75-79, 1996.
24. Pena, L. A., Fuks, Z., and Kolesnick, R. Stress-induced apoptosis and the sphingomyelin pathway. Biochem. Pharmacol., 53: 615-621, 1997.
25. Spiegel, S., Cuvillier, O., Edsall, L. C., Kohama, T., Menzeleev, R., Olah, Z., Olivera, A., Pirianov, G., Thomas, D. M., Tu, Z., Van Brooklyn, J. R., and Wang, F. Sphingosine-1-phosphate in cell growth and cell death. Ann. NY Acad. Sci., 845: 11-18, 1998.
26. Reunanen, N., Westermarck, J., Hakkinen, L., Holmstrom, T. H., Elo, I., Eriksson, J. E., and Kahari, V. M. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J. Biol. Chem., 273: 5137-5145, 1998.
27. Matthay, K. K., Harris, R., Reynolds, C. P., Shimada, H., Black, T., Stram, D. O., and Seeger, R. C. Improved event-free survival (EFS) for autologous bone marrow transplantation (ABMT) vs. chemotherapy in neuroblastoma: a phase III randomized Children's Cancer Group (CCG) study. Proc. Am. Soc. Clin. Oncol Annu. Meet., 17: 525, 1998.
28. Reynolds, C. P., Villablanca, J. G., Stram, D. O., Harris, R., Seeger, R. C., and Matthay, K. K. 13-cis-retinoic acid given after intensive consolidation therapy for high risk neuroblastoma improves event-free survival (EFS): a randomized Childrens Cancer Group (CCG) study. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 17: 2, 1998.
29. Stram, D. O., Matthay, K. K., O'Leary, M., Reynolds, C. P., Haase, G. M., Atkinson, J. B., Brodeur, G. M., and Seeger, R. C. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J. Clin. Oncol., 14: 2417-2426, 1996.
30. Meitar, D., Crawford, S. E., Rademaker, A. W., and Cohn, S. L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol., 14: 405-414, 1996.
31. Sugiura, Y., Shimada, H., Seeger, R. C., Laug, W. E., and DeClerck, Y. A. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res., 58: 2209-2216, 1998.
32. Ribatti, D., Alessandri, G., Vacca, A., Iurlaro, M., and Ponzoni, M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int. J. Cancer, 77: 449-454, 1998.
33. Wassberg, E., Pahlman, S., Westlin, J. E., and Christofferson, R. The angiogenesis inhibitor TNP-470 reduces the growth rate of human neuroblastoma in nude rats. Pediatr Res., 41: 327-333, 1997.
34. Nagabuchi, E., VanderKolk, W. E., Une, Y., and Ziegler, M. M. TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J. Pediatr. Surg., 32: 287-293, 1997.
35. v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc. Natl. Acad. Sci. USA, 96: 1591-1596, 1999.
36. Stins, M. F., Prasadarao, N. V., Zhou, J., Arditi, M., and Kim, K. S. Bovine brain microvascular endothelial cells transfected with SV40-large T antigen: development of an immortalized cell line to study pathophysiology of CNS disease. In Vitro Cell. Dev. Biol., 33: 243-247, 1997.
37. Yatohgo, T., Izumi, M., Kashiwagi, H., and Hayashi, M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Struct. Funct., 13: 281-292, 1988.
38. Seeger, R. C., Atkinson, J., and Reynolds, C. P. Neuroblastoma. In: J. F. Holland, E. Frei III, R. C. Bast, Jr., D. W. Kufe, D. L. Morton, and R. R. Weichsenbaum (eds.), Cancer Medicine, pp. 2991-3020. Philadelphia: Lea and Febiger, 1996.
39. Shimada, H., Chatten, J., Newton, W. A., Jr., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B., and Misugi, K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J. Natl. Cancer Inst., 73: 405-416, 1984.
40. 3 integrin: adhesion mechanism for transformed glial cells. J. Clin. Invest., 88: 1924-1932, 1991.
41. Lavie, Y., Cao, H., Bursten, S. L., Giuliano, A. E., and Cabot, M. C. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J. Biol. Chem., 271: 19530-19536, 1996.
42. Lavie, Y., Cao, H., Volner, A., Lucci, A., Han, T. Y., Geffen, V., Giuliano, A. E., and Cabot, M. C. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J. Biol. Chem., 272: 1682-1687, 1997.
43. Maurer, B. J., Metelitsa, L. S., Seeger, R. C., Cabot, M. C., and Reynolds, C. P. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4- hydroxyphenyl)- retinamide in neuroblastoma cell lines. J. Natl. Cancer Inst., 91: 1138-1146, 1999.
44. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65: 55-63, 1983.
45. Xu, J., Yeh, C. H., Chen, S., He, L., Sensi, S. L., Canzoniero, L. M. T., Choi, D. W., and Hsu, C. Y. Involvement of de novo ceramide biosynthesis in tumor necrosis factor-α/cycloheximide-induced cerebral endothelial cell death. J. Biol. Chem., 273: 16521-16526, 1998.
46. Erdreich-Epstein, A., Liu, M., Liu, Y., and Durden, D. L. Protein tyrosine phosphatase inhibitors in FcγRI-induced myeloid oxidant signaling. Exp. Cell Res., 237: 288-295, 1997.
47. Durden, D. L., Kim, H. M., Calore, B., and Liu, Y. The FcγRI receptor signals through the activation of hck and MAP kinase. J. Immunol., 154: 4039-4047, 1995.
48. Re, F., Zanetti, A., Sironi, M., Polentarutti, N., Lanfrancone, L., Dejana, E., and Colotta, F. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J. Cell Biol., 127: 537-546, 1994.
49. Frisch, S. M., and Francis, H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol., 124: 619-626, 1994.
50. 3: a new prognostic indicator in breast cancer. Clin. Cancer Res., 4: 2625-2634, 1998.
51. Engels, K., Fox, S. B., and Harris, A. L. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. EXS, 79: 113-156, 1997.
52. Okada, F., Rak, J. W., Croix, B. S., Lieubeau, B., Kaya, M., Roncari, L., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA, 95: 3609-3614, 1998.
53. Montesano, R., Pepper, M. S., Mohle-Steinlein, U., Risau, W., Wagner, E. F., and Orci, L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell, 62: 435-445, 1990.
54. Goodman, L. A., Liu, B. C., Thiele, C. J., Schmidt, M. L., Cohn, S. L., Yamashiro, J. M., Pai, D. S., Ikegaki, N., and Wada, R. K. Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin. Exp. Metastasis, 15: 130-139, 1997.
55. 3 in neuroblastic tumors. Am. J. Pathol., 148: 1423-1434, 1996.
56. 5 is codistributed with actin fibers. Exp. Cell Res., 234: 156-164, 1997.
57. 6. Cancer Res., 54: 2102-2107, 1994.
58. 8 in mouse and rat brain. Brain Res., 791: 271-282, 1998.
59. Cheresh, D. A., and Spiro, R. C. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J. Biol. Chem., 262: 17703-17711, 1987.
60. Zundel, W., and Giaccia, A. Inhibition of the anti-apoptotic PI(3)K/Akt/Bad pathway by stress. Genes Dev., 12: 1941-1946, 1998.
61. Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., and Ingber, D. E. Geometric control of cell life and death. Science (Washington DC), 276: 1425-1428, 1997.
62. Buckley, C. D., Pilling, D., Henriquez, N. V., Parsonage, G., Threlfall, K., Scheel-Toellner, D., Simmons, D. L., Akbar, A. N., Lord, J. M., and Salmon, M. RGD peptides induce apoptosis by direct caspase-3 activation. Nature (Lond.), 397: 534-539, 1999.
63. 3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J., 18: 882-892, 1999.
64. Brenner, B., Grassme, H. U., Muller, C., Lang, F., Speer, C. P., and Gulbins, E. L-selectin stimulates the neutral sphingomyelinase and induces release of ceramide. Exp. Cell Res., 243: 123-128, 1998.
65. Brenner, B., Koppenhoefer, U., Weinstock, C., Linderkamp, O., Lang, F., and Gulbins, E. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J. Biol. Chem., 272: 22173-22181, 1997.
66. Frisch, S. M., Vuori, K., Kelaita, D., and Sicks, S. A role for Jun-N-terminal kinase in anoikis: suppression by bcl-2 and crmA. J. Cell Biol., 135: 1377-1382, 1996.
67. Ameyar, M., Atfi, A., Cai, Z., Stancou, R., Shatrov, V., Bettaieb, A., and Chouaib, S. Analysis of human breast adenocarcinoma MCF7 resistance to tumor necrosis factor-induced cell death: lack of correlation between JNK activation and ceramide pathway. J. Biol. Chem., 273: 29002-29008, 1998.
68. 2-terminal kinase and induction of apoptosis after detachment of epithelial cells. J. Cell Biol., 139: 1017-1023, 1997.
69. Modur, V., Zimmerman, G. A., Prescott, S. M., and McIntyre, T. M. Endothelial cell inflammatory responses to tumor necrosis factor-α: ceramide-dependent and -independent mitogen-activated protein kinase cascades. J. Biol. Chem., 271: 13094-13102, 1996.
70. Adam, D., Ruff, A., Strelow, A., Wiegmann, K., and Kronke, M. Induction of stress-activated protein kinases/c-Jun N-terminal kinases by the p55 tumour necrosis factor receptor does not require sphingomyelinases. Biochem. J., 333: 343-350, 1998.
71. Zhu, P., Xiong, W., Rodgers, G., and Qwarnstrom, E. E. Regulation of interleukin 1 signalling through integrin binding and actin reorganization: disparate effects on NFκB and stress kinase pathways. Biochem. J., 330: 975-981, 1998.
72. Westwick, J. K., Bielawska, A. E., Dbaibo, G., Hannun, Y. A., and Brenner, D. A. Ceramide activates the stress-activated protein kinases. J. Biol. Chem., 270: 22689-22692, 1995.
73. Dbaibo, G. S., Obeid, L. M., and Hannun, Y. A. Tumor necrosis factor-α (TNF-α) signal transduction through ceramide: dissociation of growth inhibitory effects of TNF-α from activation of nuclear factor-κB. J. Biol. Chem., 268: 17762-17766, 1993.
74. Boland, M. P., and O'Neill, L. A. Ceramide activates NFκB by inducing the processing of p105. J. Biol. Chem., 273: 15494-15500, 1998.
75. Zhou, H., Summers, S. A., Birnbaum, M. J., and Pittman, R. N. Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis. J. Biol. Chem., 273: 16568-16575, 1998.
76. Spinedi, A., Amendola, A., Di Bartolomeo, S., and Piacentini, M. Ceramide-induced apoptosis is mediated by caspase activation independently from retinoblastoma protein post-translational modification. Biochem, Biophys. Res. Commun., 243: 852-857, 1998.
77. Spinedi, A., Di Bartolomeo, S., Di Sano, F., Rodolfo, C., Ambrosino, A., and Piacentini, M. Ceramide accumulation precedes caspase-dependent apoptosis in CHP-100 neuroepithelioma cells exposed to the protein phosphatase inhibitor okadaic acid. Cell Death Differ., 6: 618-623, 1999.
78. Kolesnick, R. N., and Kronke, M. Regulation of ceramide production and apoptosis. Annu. Rev. Physiol., 60: 643-665, 1998.
79. Mathias, S., Pena, L. A., and Kolesnick, R. N. Signal transduction of stress via ceramide. Biochem. J., 335: 465-480, 1998.
80. Dbaibo, G. S., Perry, D. K., Gamard, C. J., Platt, R., Poirier, G. G., Obeid, L. M., and Hannun, Y. A. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J. Exp. Med., 185: 481-490, 1997.
81. Tepper, A. D., de Vries, E., van Blitterswijk, W. J., and Borst, J. Ordering of ceramide formation, caspase activation, and mitochondrial changes during CD95- and DNA damage-induced apoptosis. J. Clin. Invest., 103: 971-978, 1999.